Updates are available Correction dated 2022-12-28

Article History

Received: 30 March 2022

Accepted: 13 June 2022

First Online: 23 June 2022

Change Date: 28 December 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1186/s10194-022-01529-2

Declarations

:

: This survey used only anonymized data, and the ethical committee review was therefore not required, and no new individual level consent was obtained for the use of the data. However, the survey was conducted in consideration of the Declaration of Helsinki (revised October 2013) by the World Medical Association and the Ethical Guidelines for Medical Research Involving Human Subjects.

: Not applicable.

: HS, HK, YS and NK are employees of Otsuka Pharmaceutical Co., Ltd.FS received consultant fee from Otsuka Pharmaceutical Co., Ltd., during the conduct of the study; consulting fees from Otsuka Pharmaceutical Co., Ltd., Eli-Lilly Co., Ltd., and Amgen Co. Ltd.; lecture Honoraria from Otsuka Pharmaceutical Co., Ltd., Eli-Lilly Co., Ltd., and Amgen Co., Ltd., outside the submitted work. KH received consulting fees from Otsuka Pharmaceutical Co., Ltd., during the conduct of the study; consulting fees from Otsuka Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Amgen Astellas BioPharma K.K., and Lundbeck Japan K.K.; lecture Honoraria from Otsuka Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Eisai Co., Pfizer Japan, Daiichi Sankyo Co., Ltd., MSD Co., Ltd., Amgen Astellas BioPharma K.K., Ltd., and Lundbeck Japan K.K., outside the submitted work. HI received consulting fees Otsuka Pharmaceutical Co., Ltd., during the conduct of the study; consulting fees from Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd.; Daiichi Sankyo Co., Eli Lilly Japan K.K, lecture Honoraria from Otsuka Pharmaceutical Co., Ltd., Eli Lilly Japan K.K, Amgen K.K., Daiichi Sankyo Co., Ltd., and Eisai Co., Ltd.; manuscript writing fee from Sawai Pharmaceutical Co., Ltd.; educational event fees from Lundbeck Japan K.K., outside the submitted work. TT received consulting fees from Otsuka Pharmaceutical Co., Ltd., during the conduct of the study; grants or contracts from Eisai Co., Ltd., Amgen Inc., Eli Lilly Japan K.K., and Allergan Japan K.K.; consulting fees from Otsuka Pharmaceutical Co., Ltd.; honoraria for lectures from Otsuka Pharmaceutical Co., Ltd., Eisai Co., Ltd., Amgen Inc., and Eli Lilly Japan K.K., outside the submitted work. TN received consulting fees from Otsuka Pharmaceutical Co., Ltd., during the conduct of the study; consulting fees from Dainippon Sumitomo Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd.; grants or contracts from I&H Co., Ltd., and Nakagawa Pharmacy Co.; lecture Honoria from Pfizer Japan Inc., MSD K.K., Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Boehringer Ingelheim International GmbH., Eli Lilly Japan K.K., Baxter Ltd., Mitsubishi Tanabe Pharma Co., Otsuka Pharmaceutical Co., Ltd. and Novartis Pharma K.K., outside the submitted work.